RJA
SUPN icon

Raymond James & Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Raymond James & Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,474
Closed -$379K – 3965
2023
Q1 		$379K Buy
+10,474
New +$403K ﹤0.01% 3087
2021
Q3 		– Sell
-9,755
Closed -$300K – 4251
2021
Q2 		$300K Sell
9,755
-4,281
-31% -$131K ﹤0.01% 3436
2021
Q1 		$367K Sell
14,036
-6,157
-30% -$172K ﹤0.01% 3231
2020
Q4 		$508K Sell
20,193
-274
-1% -$5.9K ﹤0.01% 2798
2020
Q3 		$427K Buy
20,467
+2,140
+12% +$48.6K ﹤0.01% 2747
2020
Q2 		$435K Sell
18,327
-5,862
-24% -$130K ﹤0.01% 2684
2020
Q1 		$435K Buy
24,189
+706
+3% +$14.8K ﹤0.01% 2509
2019
Q4 		$557K Sell
23,483
-27,926
-54% -$678K ﹤0.01% 2648
2019
Q3 		$1.41M Buy
51,409
+5,666
+12% +$168K ﹤0.01% 1974
2019
Q2 		$1.51M Buy
45,743
+2,271
+5% +$77.8K ﹤0.01% 1960
2019
Q1 		$1.52M Sell
43,472
-2,562
-6% -$95.3K ﹤0.01% 1943
2018
Q4 		$1.53M Buy
46,034
+36,942
+406% +$1.59M ﹤0.01% 1821
2018
Q3 		$458K Sell
9,092
-1,227
-12% -$60.6K ﹤0.01% 2766
2018
Q2 		$618K Buy
10,319
+1,557
+18% +$80.7K ﹤0.01% 2536
2018
Q1 		$401K Buy
8,762
+1,570
+22% +$65.5K ﹤0.01% 2703
2017
Q4 		$287K Sell
7,192
-2,262
-24% -$89.4K ﹤0.01% 2866
2017
Q3 		$378K Buy
9,454
+1,396
+17% +$60.4K ﹤0.01% 2645
2017
Q2 		$347K Buy
8,058
+151
+2% +$5.37K ﹤0.01% 2639
2017
Q1 		$247K Sell
7,907
-17,210
-69% -$461K ﹤0.01% 2815
2016
Q4 		$634K Buy
25,117
+3,823
+18% +$85.4K ﹤0.01% 2187
2016
Q3 		$527K Buy
21,294
+270
+1% +$6.11K ﹤0.01% 2252
2016
Q2 		$428K Sell
21,024
-5,487
-21% -$97.3K ﹤0.01% 2186
2016
Q1 		$404K Buy
26,511
+11,312
+74% +$148K ﹤0.01% 2163
2015
Q4 		$204K Sell
15,199
-25,042
-62% -$387K ﹤0.01% 2323
2015
Q3 		$565K Buy
+40,241
New +$748K ﹤0.01% 1875

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's SUPN Position: Q2 2023 in Review

Raymond James & Associates sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 10,474 shares — an estimated $379K sold.

Raymond James & Associates first reported a position in SUPN in Q3 2015 and held it in 25 quarters. The position peaked at $1.53M in Q4 2018. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • Raymond James & Associates reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,474 Supernus Pharmaceuticals shares in Q2 2023, an estimated $379K.
  • Raymond James & Associates first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 25 quarters.
  • Raymond James & Associates's Supernus Pharmaceuticals position peaked at $1.53M in Q4 2018.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.